U.S. Markets closed
  • S&P Futures

    -26.00 (-0.79%)
  • Dow Futures

    -158.00 (-0.59%)
  • Nasdaq Futures

    -129.50 (-1.14%)
  • Russell 2000 Futures

    -9.70 (-0.62%)
  • Crude Oil

    +0.02 (+0.06%)
  • Gold

    +0.80 (+0.04%)
  • Silver

    +0.01 (+0.06%)

    -0.0074 (-0.6305%)
  • 10-Yr Bond

    +0.0540 (+6.91%)
  • Vix

    -2.69 (-6.68%)

    -0.0059 (-0.4525%)

    +0.2820 (+0.2704%)

    -0.26 (-0.00%)
  • CMC Crypto 200

    +20.99 (+8.65%)
  • FTSE 100

    -1.05 (-0.02%)
  • Nikkei 225

    -86.57 (-0.37%)

4 Healthcare Stocks Looking For A Healthy Start On Monday (1/28/19)

CORAL GABLES, FL / ACCESSWIRE / January 28, 2019 / The healthcare stock market has increasingly attracted more attention over the last few months, as more companies have focused their efforts on developing new treatment options for patients suffering from a myriad of diseases. With headlines popping up left and right, news surrounding these innovative companies in the healthcare industry has worked to attract investors looking for potential opportunities in the space. As an industry predicated on improving the quality of life for consumers, Premier Health Group (OTC:PHGRF) (CSE:PHGI), Novavax Inc (NVAX), Trevena Inc (TRVN), and Teladoc Health Inc (TDOC) represent four healthcare companies determined to invest in the betterment of the global health market.

Premier Health Group (OTC:PHGRF) (CSE:PHGI) is a company focused on developing nuanced approaches that combine human skill-based expertise with state-of-the-art technologies used throughout the healthcare industry to create the best-possible care solutions for their growing patient network.

Over the course of the last few months, the Company has seen impressive gains as investors and consumers have come to realize the lengths Premier will go to in order to create the best possible products, and offer the highest quality services, for consumers.

Towards the tail-end of last week, Premier Health Group (OTC:PHGRF) (CSE:PHGI) announced two key new hires to support its anticipated growth in 2019 and beyond.

Following the Company's announcement, Dr. Essam Hamza, CEO of Premier Health Group (OTC:PHGRF) (CSE:PHGI) said, ''As we further our expansion, we are thrilled to officially bring on two new members to the Premier leadership team. Mr. Mena Beshay has accepted the role of CFO with the company, and Ms. Kanchan Thindal will take on the position of COO. These two highly educated individuals bring extensive financial, operations and strategic experience to Premier that will be a major asset as we enter our next phase of growth and further our patient-centric mission.''

For More Information On Premier Health Group, Click Here

Novavax Inc (NVAX) announced earlier this month that results were now available from its Phase 2 clinical trial of NanoFlu™. The trial compared the safety and immune responses of various quadrivalent formulations of NanoFlu, with or without Novavax' Matrix-M™ adjuvant, with two U.S.-licensed influenza vaccines in 1,375 healthy adults 65 years of age and older.

In a press release regarding the announcement, Gregory Glenn, President of Research and Development of Novavax, said, "The superior immunogenicity against wild-type H3N2 viruses holds promise that NanoFlu will more effectively address the mismatch between circulating viruses and the strains included in most commercial vaccines due to genetic drift and vaccine virus egg adaptation.''

For More Information On Novavax Inc., Click Here

Trevena Inc (TRVN) today announced that the Company had received the Official Type A meeting minutes from the U.S. Food and Drug Administration regarding the Complete Response Letter received for their oliceridine New Drug Application. Per the details of the announcement, the FDA both agreed that the Company's current safety database will support labeling at a maximum daily dose of 27 mg, as well as that the Company can conduct a study in healthy volunteers to collect the requested QT interval data and that the study should include placebo- and positive-control arms.

Following this announcement, Carrie L. Bourdow, President and Chief Executive Officer of Trevena, said, "We are encouraged by the productive discussion with FDA, which we believe has provided a path to resubmit the oliceridine NDA. We remain committed to our mission of ensuring access to safe and effective treatment options for hospital patients who require an IV opioid to manage their moderate to severe acute pain.''

For More Information on Trevena Inc., Click Here

Teladoc Health Inc (TDOC), one of the global leaders in virtual healthcare solutions, announced earlier this month that it was increasing U.S. availability of Teladoc Back Care, a new, personalized, online back pain treatment program. With this new addition to the Teladoc Health care continuum, patients and employers can now leverage virtual care to reduce the intensity, frustration, and impact of back pain.

Dan Trencher, senior vice president, Product and Corporate Strategy for Teladoc Health, commented on the announcement, saying, ''As we continue to expand our portfolio and add high value, complementary services for our clients and members, results show that low back pain - one of the most common musculoskeletal concerns in healthcare - can be effectively treated virtually.''

For More Information On Teladoc Health Inc., Click Here

What Is Stock Price (StockPrice.com)?

Stock Price is defined as the price of a single share of a number of saleable stocks of a public company. A stock price is the highest amount an investor or trader is willing to pay for the stock, or the lowest amount that it can be bought for.

StockPrice.com was created for everyone that wants the latest stock quotes, stock charts, company news, and the best financial content.

At Stock Price (StockPrice.com), you get free stock quotes, up-to-date news, international market data, social interaction and the best financial content that will help you manage your financial life.

Legal Disclaimer

Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. JSG Communications, LLC which owns www.StockPrice.com is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release.

JSG Communications, LLC, which owns www.StockPrice.com, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. JSG Communications, LLC, which owns www.StockPrice.com, may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two.

Pursuant to an agreement between MIDAM VENTURES, LLC an affiliate of JSG COMMUNICATIONS LLC and Premier Health Group Inc. we were hired for a period from 10/1/2018 - 4/1/2019 to publicly disseminate information about Premier Health Group Inc. including on the Website and other media including Facebook and Twitter. We were paid $300,000 (CASH) for & were paid ''500,000'' shares of restricted common shares (as of 1/28/2019). We own zero shares of Premier Health Group Inc., which we purchased in the open market. Once the (6) Six-month restriction is complete on 4/1/2019 we plan to sell the ''500,000'' shares of Premier Health Group Inc. that we hold currently in restricted form during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of Premier Health Group Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information Please click here for full disclaimer.



SOURCE: Stock Price